Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05718869 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

StatusActive, Not Recruiting
PhasePhase 2
Started2023-05-18
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Sep 8, 2026 → Jul 27, 2027
See other at-risk trials from City of Hope Medical Center

Amendment history

2026-10-02
Primary completion pushed: 2026-09-08 → 2027-07-27
Completion pushed: 2026-09-08 → 2027-07-27
2026-05-06
Study Status v5
Primary completion date2026-04-19→2026-09-08
Completion date2026-04-19→2026-09-08
2025-11-03
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v4
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-10-19→2026-04-19
Completion date2025-10-19→2026-04-19
Enrollment targetestimated 25→confirmed 26
Study sitesdetails revised at 3 of 3 sites
2025-08-18
Study Status v3
Re-verified, no change to tracked fields
2024-08-13
Study Status, Contacts/Locations v2
Study sites1→3
2023-10-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2024-07-15→2025-10-19
Completion date2024-07-15→2025-10-19
Start dateestimated 2023-07-15→confirmed 2023-05-18
Study sitesdetails revised at 1 of 1 site
2023-01-30
Original filing
This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein that signals cancer cells to multiply. This may stop the growth and spread of cancer cells. Giving tafasitamab and zanubrutinib in combination may kill more cancer cells in patients with CLL/SLL than giving either treatment alone.
Trial Details
NCT Number NCT05718869
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 26 participants
Start Date 2023-05-18
Primary Completion 2027-07-27 (estimated)
Study Completion 2027-07-27 (estimated)
Updated on ClinicalTrials.gov 2026-10-01